Scholars Central

Conference abstractPublished 17 Jul 2017

Evaluation of cationic channel TRPV2 as a novel biomarker and therapeutic target in leukemia-implications concerning the resolution of pulmonary dysfunction

Authors: Fouad Azizi, Siveen K Sivaraman, Kirti S Prabhu, Maysaloun Merhi, Aeijaz S Parray, Abdelilah Arredouani, Mohamed Chikri, Shahab K Uddin, Said Dermime, Ibrahim A Janahi, Ramzi M Mohammad

Hamad Medical Corporation, Qatar Qatar Biomedical Research Institute, Qatar

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Patients treated during advanced and aggressive stages of leukemia face the risk of complications including pulmonary dysfunction and toxicity due to chemotherapy radiotherapy, and infiltration of leukemic blast cells (LBCs) into the lungs. Therefore, there is an urgent need for alternative or adjuvant therapeutic strategies. In this study, we sought to identify a molecular component of LBCs that, clinically, would serve as a reliable biomarker and can be exploited as a therapeutic target for hard to treat leukemia. The transient receptor potential vanilloid channel type 2 (TRPV2) exhibits oncogenic activity and plays a crucial role in immune inflammatory processes. Here, we found that TRPV2 mRNA levels were significantly higher in LBCs compared to normal human peripheral blood mononuclear cells (PBMCs). Alternative mRNA splicing was evidenced by upregulation of TRPV2 full length isoform (TRPV2[97kDa]) and downregulation of its short pore-less isoform (TRPV2[72kDa]) in LBCs. However, the opposite was found in PBMCs. Pharmacological modulation of TRPV2 by tranilast and SKF96365 inhibited LBCs proliferation through caspase-mediated apoptosis/cell cycle arrest, and involved the mitogen-activated protein (MAP) kinase pathways: extracellular signal-regulated kinases (ERKs), and the p38 group of protein kinases. Both drugs, in a dose-dependent manner, decreased and increased levels of TRPV2[97kDa] and TRPV2[72kDa] respectively, and downregulated the expression of pathogenic surface markers CD33 and CD38 in LBCs. TRPV2 siRNA mimicked tranilast and SKF96365 antiproliferative effects by triggering apoptosis/cell cycle arrest. Therefore, TRPV2 is a pharmacodynamic biomarker with pathogenesis relevance that can be targeted by anti-inflammatory drugs, and merits further exploration for potential clinical use.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalCancer Science & Therapy
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Fouad Azizi”
  • BylineArticles whose byline prints “Siveen K Sivaraman”
  • BylineArticles whose byline prints “Kirti S Prabhu”
  • BylineArticles whose byline prints “Maysaloun Merhi”
  • BylineArticles whose byline prints “Aeijaz S Parray”
  • BylineArticles whose byline prints “Abdelilah Arredouani”
  • BylineArticles whose byline prints “Mohamed Chikri”
  • BylineArticles whose byline prints “Shahab K Uddin”